Biography
Dr. Laura van ‘t Veer is a world-renowned molecular biologist whose research focuses on precision medicine to advance patient management. She is co-leader of the Breast Oncology Program at UCSF and co-founder of Agendia Inc. As inventor of MammaPrint she has made a seminal impact on “rightsizing” the treatment of breast cancer. A recent publication on the MINDACT trial shows that 46% of breast cancer patients who are clinically high risk and considered for chemotherapy, can safely forgo this treatment based on a Low Risk MammaPrint result. Dr. van ‘t Veer is co-PI of the multicenter adaptive clinical trial I-SPY2 overseeing FDA-IDE ‘Response-Predictive-Subtyping’ companion diagnostics. She has over 300 peer-reviewed scientific articles and is co-inventor of 9 patents. Dr. van 't Veer received the prestigious European Union Women Innovator Award, 2nd prize in 2014, the 2015 European Patent Office Inventor Award, and is a 2020 PMWC Luminary award recipient.